Skip to Main Content

The Seattle biotech Omeros (OMER) has reported sharply lower sales of its cataract surgery drug in the fourth quarter after losing favorable Medicare reimbursement at the end of last year.

Lacking a reimbursement fix, Omeros offered a bleak sales outlook for this year for the drug, Omidria, raising the risk that the company might end up in default on a business loan.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!